All relevant data are within the paper and its Supporting Information files.

Introduction {#sec004}
============

Visceral leishmaniasis (VL) is an infection caused by various species of *Leishmania*, an intracellular protozoan parasite. Currently, VL is among the six endemic prioritized diseases in the world \[[@pntd.0005562.ref001]\]. In humans, infection with *Leishmania* can cause a broad spectrum of symptoms ranging from a clinically silent infection to a fatal visceral disease \[[@pntd.0005562.ref002]\]. In an urban environment, dogs are the main reservoir of the disease, but many stay asymptomatic, showing no clinical signs \[[@pntd.0005562.ref003], [@pntd.0005562.ref004], [@pntd.0005562.ref005]\].

A2 is a stress response protein from *L*. *donovani* and it is expressed in amastigote and in promastigote cultures. It corresponds to the specific virulence factor (*Ld*VFA2) and has been shown to be required for *L*. *donovani* amastigote survival in visceral organs of mice \[[@pntd.0005562.ref006], [@pntd.0005562.ref007], [@pntd.0005562.ref008]\]. A2 proteins are composed mostly of a variable number of 10-amino-acid repeats and their molecular weight varies from 45 to 100 kDa \[[@pntd.0005562.ref009]\]. *Ld*VFA2 antigens, administered as recombinant protein (rec*Ld*VFA2) or DNA, are protective against *L*. *donovani*, *L*. *amazonensis* and *L*. *chagasi* infections in mice \[[@pntd.0005562.ref010], [@pntd.0005562.ref011], [@pntd.0005562.ref012]\], dogs \[[@pntd.0005562.ref013]\] and macaques \[[@pntd.0005562.ref014]\]. Anti- *Ld*VFA2 antibodies have been detected in sera samples from human patients with active visceral leishmaniasis, confirming that *Ld*VFA2 proteins are expressed during infection \[[@pntd.0005562.ref010], [@pntd.0005562.ref015]\]. These findings suggest that studies of *Ld*VFA2 proteins antigenic properties might have great potential for the development of vaccines, therapeutics and diagnostics for leishmaniasis.

In this work, we report the mapping of B-cell continuous epitopes of rec*Ld*VFA2, production by chemical synthesis of a rec*Ld*VFA2-derived synthetic epitope and its use as antigen for canine visceral leishmaniasis (CVL) diagnosis. Epitope mapping was achieved by peptide-scanning of the rec*Ld*VFA2 sequence using the Spot-synthesis technique \[[@pntd.0005562.ref016]\]. This method is an easy and very flexible technique for simultaneous parallel peptides chemical synthesis on membrane supports. Furthermore, it allows a rapid and low-cost access to a large number of peptides for systematic epitope analysis \[[@pntd.0005562.ref017]\]. Sixty-five overlapping peptides (15-mer frameshifted by 3 residues) covering the complete amino acid sequence of rec*Ld*VFA2 were synthesized on cellulose membranes. Five continuous epitopes corresponding to the non-repetitive N-ter region of rec*Ld*VFA2 (MKIRSVRPLVVLLVC, RSVRPLVVLLVCVAA, RPLVVLLVCVAAVLA, VVLLVCVAAVLALSA and LVCVAAVLALSASAE, region 1--28) were mapped using anti- rec*Ld*VFA2 dog sera and one epitope was located within the repetitive units (PLSVGPQAVGLSVG, region 67--81 and 122--135) using an anti-rec*Ld*VFA2 mAb. An epitope from N-ter (MKIRSVRPLVVLLVC) and another from the C-ter part (PLSVGPQAVGLSVG) were selected and chemically assembled in tandem, to yield a soluble bi-epitope peptide. The bi-epitope used as coating antigen in ELISA accurately distinguish (high sensitivity and specificity) sera of CVL dogs from sera of non-infected dogs.

Methods {#sec005}
=======

In order to discover a new antigen for use in CVL diagnostics tests, dog's polyclonal and monoclonal anti-sera *Ld*VFA2 were used to map epitopes. An initial screening was made to select polyclonal antisera with high affinity for *Ld*VFA2 protein and low affinity for the crude extract of *Leishmania infantum*. The epitopes mapped to the selected polyclonal sera and with the specific monoclonal sera were analyzed and two were selected and synthesized as a bi-peptide. This bi-epitope peptide was called rec*Ld*VFA2 derived and it was tested as antigen for CVL diagnosis. The choice of *L*. *donovani* protein for epitope search for use in *L*. *infantum* diagnostic test is due to extensive research on this protein (recVFA2), amino acid sequence availability and biological findings indicating that there is interspecific cross-reactivity.

Ethics statement {#sec006}
----------------

Approval to use the sera samples was obtained from the Committee on Ethics of Animal Experimentation (CETEA, national guidelines Lei 11.794, de 8 de outubro de 2008) from this UFMG (CETEA--protocol 44/2012).

Production *leishmania* (leishmania*) infantum* antigen *(Li*A*)* and rec*Ld*VFA2 {#sec007}
---------------------------------------------------------------------------------

*L*. *infantum* (MHOM/BR/1975/BH46) was grown at 24°C in Schneider´s medium (Sigma, St. Louis, MO, USA) supplemented with 20% heat-inactivated fetal bovine serum (FBS; Sigma), 200 U/mL penicillin and 100 μg/mL streptomycin, at pH 7.2. Total soluble antigens of *L*. *infantum* (*Li*A) was prepared from stationary phase promastigotes, submitted to 7 cycles of freezing (liquid nitrogen) and thawing (42°C), followed by ultrasonication (Ultrasonic processor, GEX600), with cycles of 10 sec for 2 min at 35 MHz. Extracts were then submitted to centrifugation at 8000 × *g* for 20 min at 4°C. The supernatant was collected and stored at −70°C. rec*Ld*VFA2, a recombinant form of A2, was expressed and purified as previously described \[[@pntd.0005562.ref015]\].

Dog sera and monoclonal antibody against rec*Ld*VFA2 {#sec008}
----------------------------------------------------

For epitope mapping, sera from seventy-three dogs immunized with rec*Ld*VFA2 were obtained from the laboratory HERTAPE-KALIER Health Animal S.A. For diagnostic test, serum of dogs from a CVL non-endemic area and giving negative results for *L*. *infantum* in immunofluorescence antibody test (IFAT) and confirmed by parasitological test and microscopic analysis of bone marrow aspirates were considered to be non-infected and used as the control group (NI, n = 101). *Leishmania*-infected dog sera (I, n = 101) were obtained from an endemic area for CVL in the Minas Gerais State of Brazil. Infection status was determined by parasitological test, the positivity was confirmed by microscopic analysis of bone marrow aspirates. The positive and negative status was further confirmed by real time PCR. Samples from dogs experimentally infected with *Trypanosoma cruzi* (TC, n = 10), but parasitologically negative for *Leishmania*, were included in this study to evaluate possible cross-reactivity. All sera used for diagnostic test were obtained from sera bank already existing of Laboratory of Immunology and Genomics of Parasites, Federal University of Minas Gerais (UFMG/BR). The anti- *L*. *donovani* virulence factor A2 murine monoclonal antibody (mAb-anti rec*Ld*VFA2) was kindly provided by Dr. Greg Matlashewski, McGill University, Quebec, Canada.

Identification new antigen for CVL diagnostic {#sec009}
---------------------------------------------

### Selection of polyclonal sera by ELISA {#sec010}

Falcon flexible microtitration plates (Becton Dickinson France S.A.) were coated overnight at 5^°^C with 100 μl of a 10 μg/ml solution of *Li*A and 2 μg/ml solution of rec*Ld*VFA in 0.02M sodium bicarbonate buffer, pH 9.6. Plates were washed with PBS 1x, 0.1% Tween 20 (v/v) and then blocked with PBS 1x, 0.1% Tween 20 and 2% caseine (w/v) for 1 h at 37°C. Anti-rec*Ld*VFA dog sera (diluted 1:100) were added to respective wells. Plates were incubated for 2 h at 37°C. Binding was detected using an anti-Dog IgG peroxidase conjugated (Sigma) diluted 1:5000 in blocking buffer. After 1 h at 37°C and washing, the peroxidase substrate was added. The reaction was stopped with H~2~SO~4~ 1N after 30 minutes and the resulting colour was measured at 492 nm with an automated microtiter plate reader (Model 450, Bio-Rad). All measurements were made in triplicate.

B-cell epitope mapping of rec*Ld*VFA {#sec011}
------------------------------------

### Spot peptides synthesis on cellulose membrane {#sec012}

Seventy-five 15-mer overlapping peptide frameshifted by three amino acids derived from the sequence of A2 protein (GenBank accession number: AAB30592.1) were synthesized on a cellulose membrane (Intavis, Koln, Germany) according to \[[@pntd.0005562.ref018]\] and an ASP222 robot (Intavis) was used for the coupling steps. N-terminal acetylation of the peptides was also performed to increase their stability. After peptide sequences had been assembled, the side-chain protecting groups were removed by trifluoracetic acid treatment as described before \[[@pntd.0005562.ref019]\].

### Immunoassay with cellulose membrane-bound peptides {#sec013}

After an overnight saturation step with blocking buffer (Genosys, France), the set of membrane bound peptides was probed by incubation with serum from four dogs immunized with recA2p (diluted 1:100) for 2 h. Polyclonal antibodies binding was detected by using an alkaline phosphatase-conjugated anti-dog antibody (Sigma) diluted 1:2000 for 1 h, and by the addition of a phosphatase substrate \[5-bromo-4-chloro-3-indolyl phosphate (BCIP) and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (Sigma), which generates a blue precipitate over spots harboring a peptide recognized by antibodies. A similar procedure was adopted for assays with mAb, used at 2.0 μg/ml. In this case, peptide reactivity was revealed by using an alkaline phosphatase-conjugated anti-mouse antibody (Sigma) diluted 1:2000. To allow its reuse, the membrane was sequentially treated with dimethylformamide, 1% SDS, 0.1% 2-mercaptoethanol in 8 M urea, ethanol/water/acetic acid (50:40:10 vol/vol/vol) and, finally, methanol to remove the precipitated dye and molecules bound to the peptides. The intensity of spots colors were arbitrary quantified using ImageJ software (NIH, Bethesda, MD, USA). The highest reactive spot for each type of epitope mapping (spot 3, for mapping using polyclonal immunized dog sera and spot 48 for mapping using mAb) was considered as presenting 100% of reactivity. The reactivity of all other spots was expressed as percentage of values according to the highest reactive spots.

### Bi-epitope synthesis of rec*Ld*VFA2 derived {#sec014}

Based on the results of peptide array immunoassay, it was prepared a 34-mer peptide containing two sequences of fifteen amino acids residues in tandem: sequence PLSVGPQAVGLSVG from repetitive part of A2 protein was linked by a Gly-Gly dipeptide to the 15-mer sequence MKIRSVRPLVVLLVC from the non-repetitive part, in order to bring together regions that are apart from each other in the linear sequence of the target peptide. With the purpose of facilitate subsequent affinity based purification of the anti-peptide antibodies, two amino acid residues were added, Lys to the N-ter and Cys to C-ter extremities, respectively. The 34-mer peptide was synthesized manually by F-moc chemistry on a Wang resin (Novabiochem) as described \[[@pntd.0005562.ref020]\] adapted by \[[@pntd.0005562.ref021]\]. After synthesis the protecting groups of side chains were deprotected and the peptide was released from the resin by using TFA in the presence of appropriate scavengers. Then, the peptide was lyophilized and its mass confirmed by mass spectrometry. The synthetic bi-epitope rec*Ld*VFA2 derived (20 mg) was diluted in 1 ml of PBS and used as antigenic preparation to coat ELISA plates. A non-related peptide CRCKPDQGRLRCGYK (nrpep) was also synthesized to be used as negative control.

Diagnosis of canine leishmaniasis using synthetic bi-epitope {#sec015}
------------------------------------------------------------

One hundred and one sera from infected dogs were used (I), as well as 101 sera from dogs without a history of *Leishmania* infections (NI) and 10 sera from dogs experimentally infected by *T*. *cruzi* (TC), to verify if the bi-epitope recLdVFA2 derived is a good candidate to be antigen in CVL diagnostic test. Maxisorb flexible microtitration plates were coated overnight at 5°C with 100 μL of synthetic peptide solution (10 μg/mL) in 0.02 M sodium bicarbonate buffer, pH 9.6. Assays were performed as previously described \[[@pntd.0005562.ref022]\]. Sera were diluted 1:100 and absorbance values were determined at 492 nm with a Titertek Multiscan spectrophotometer. All measurements were made in triplicate. Standard EIE-LCV kit for the leishmaniasis diagnosis was used for comparison. This test is the most used in the clinical and serologic testing ELISA for LCV is a good test for use in the field epidemiological serum screening due to its convenience and low cost.

Statistical analysis {#sec016}
--------------------

All data comparisons were tested for significance by using unpaired Student's *t* test or Kruskal--Walls test. Differences were considered statistically significant when *P* values were \< 0.05. The lower limit of positivity (cut-off) for bi-epitope and EIE-LCV was established for optimal sensitivity and specificity using the Receiver Operator Curve (ROC curve). The cut-off was chosen based on the point that provides the maximum of the sum of the sensibility and specificity \[[@pntd.0005562.ref023]\]. The performance of each test was evaluated according to the sensitivity (Se), specificity (Sp), positive predictive value (PPV), negative predictive value (NPV), area under the curve (AUC) and accuracy (ACC).

Statistical analyses were performed using GraphPad Prism (version 5.0) and R package for Windows ([www.r-project.org](http://www.r-project.org/)) (version 3.1.0).

Results {#sec017}
=======

Identification new antigen for CVL diagnostic {#sec018}
---------------------------------------------

### Selection of dog sera for B-cell epitope mapping {#sec019}

A study with 73 sera from dogs immunized with rec*Ld*VFA2 protein was carried using ELISA to select sera for epitope mapping purposes. Data showed in [Table 1](#pntd.0005562.t001){ref-type="table"} indicate that anti-recVFA2 antibodies were present in all tested sera samples (100%). ELISA values (Abs = 492 nm) varied between 0.195 and 1.4, with an average value of 0.721 ± 0.240. Anti- *Li*A antibodies from dogs immunized with rec*Ld*VFA2 were also measured. Sixty-nine of 73 sera samples, (94.5%) also exhibited cross-reactivity with *Li*A. ELISA values (Abs = 492 nm) varied between 0.055 and 1.10, with an average value of 0.410 ± 0.230. Sera from dogs immunized with rec*Ld*VFA2 which presented very low cross-reaction against *Li*A (Abs values less than 0.10) were used for the epitope mapping of rec*Ld*VFA2. Based in these criteria, sera from 4 dogs with highest ratio between the reactivity for rec*Ld*VFA2 and *Li*A were selected.

10.1371/journal.pntd.0005562.t001

###### ELISA reactivity of 73 sera of dogs immunized with rec*Ld*VFA2 against rec*Ld*VFA2 and *LiA*.

![](pntd.0005562.t001){#pntd.0005562.t001g}

  Dog serum number   Reactivity against                               Dog serum number                                 Reactivity against                                                    
  ------------------ ------------------------------------------------ ------------------------------------------------ -------------------- ------------------------------------------------ ------------------------------------------------
  1                  0.771                                            0.309                                            38                   0.395                                            0.209
  2                  0.941                                            0.382                                            39                   0.661                                            0.45
  3                  0.589                                            0.234                                            40                   0.973                                            0.365
  4                  0.832                                            0.327                                            41                   1.331                                            0.426
  5                  0.548                                            0.294                                            42                   1.077                                            0.342
  6                  0.282                                            0.239                                            43                   0.761                                            0.336
  7                  0.939                                            0.257                                            44                   0.891                                            0.356
  **8**              **0.747**[\*](#t001fn002){ref-type="table-fn"}   **0.069**[\*](#t001fn002){ref-type="table-fn"}   **45**               **0.868**[\*](#t001fn002){ref-type="table-fn"}   **0.065**[\*](#t001fn002){ref-type="table-fn"}
  9                  0.644                                            0.214                                            46                   0.802                                            0.218
  10                 0.649                                            0.255                                            47                   0.949                                            0.349
  11                 0.602                                            0.38                                             **48**               **1.332**[\*](#t001fn002){ref-type="table-fn"}   **0.095**[\*](#t001fn002){ref-type="table-fn"}
  12                 0.583                                            0.755                                            49                   0.541                                            0.711
  13                 0.678                                            0.162                                            50                   0.328                                            0.798
  14                 0.502                                            0.573                                            51                   0.794                                            0.736
  15                 0.549                                            0.753                                            52                   0.86                                             0.341
  16                 0.715                                            0.566                                            53                   0.697                                            0.69
  17                 0.892                                            0.956                                            54                   0.554                                            0.466
  18                 0.430                                            0.584                                            55                   0.500                                            0.25
  19                 0.339                                            0.709                                            **56**               **1.228**[\*](#t001fn002){ref-type="table-fn"}   **0.095**[\*](#t001fn002){ref-type="table-fn"}
  20                 0.804                                            0.302                                            57                   0.623                                            0.586
  21                 0.351                                            0.346                                            58                   0.729                                            0.627
  22                 0.504                                            0.186                                            59                   0.445                                            0.446
  23                 0.932                                            0.327                                            60                   0.58                                             0.36
  24                 1.4                                              0.631                                            61                   0.571                                            0.847
  25                 0.853                                            0.31                                             62                   0.574                                            0.646
  26                 0.748                                            0.317                                            63                   0.439                                            0.455
  27                 0.839                                            0.92                                             64                   0.594                                            0.18
  28                 1.116                                            1.11                                             65                   0.642                                            0.288
  29                 0.712                                            0.293                                            66                   0.522                                            0.358
  30                 0.622                                            0.846                                            67                   0.195                                            0.200
  31                 0.729                                            0.509                                            68                   0.61                                             0.449
  32                 0.858                                            0.25                                             **69**               **0.767**[\*](#t001fn002){ref-type="table-fn"}   **0.056**[\*](#t001fn002){ref-type="table-fn"}
  33                 0.785                                            0.278                                            70                   0.781                                            0.256
  34                 0.72                                             0.385                                            71                   0.996                                            0.267
  35                 1.033                                            0.486                                            72                   0.659                                            0.055
  36                 0.733                                            0.38                                             73                   0.74                                             0.300
  37                 0.688                                            0.369                                                                                                                  

ELISA plates were coated with of *Li*A and rec*Ld*VFA in 0.02M sodium bicarbonate buffer. Dog sera anti-rec*Ld*VFA were diluted 1:100 were added to respective wells. Peroxidase conjugated anti-IgG dog (Sigma) was 1:5000. The reactivity was measured at 492 nm with a microtiter plate reader (Model 450. Bio-Rad). All measurements were made in triplicate.

**\***Bold numbers indicate sera that gave a good reactivity response with the rec*Ld*VFA and a negative response with *Li*A.

### Identification of B-cell epitopes of rec*Ld*VFA2 {#sec020}

To map the epitopes of rec*Ld*VFA2, it was used Spot-synthesis method \[[@pntd.0005562.ref019], [@pntd.0005562.ref024]\]. A set of 75 overlapping peptides (15 residues, offset by 3 residues) corresponding to the complete amino acid sequence of rec*Ld*VFA2 was synthesized in a cellulose membrane ([Table 2](#pntd.0005562.t002){ref-type="table"}). At the end of the synthesis, peptides remain covalently bound to the membrane and can be assayed for antibody reactivity. Four different sera from dogs immunized with rec*Ld*VFA2 and an anti-rec*Ld*VFA2 monoclonal antibody were used to probe the set of peptides for antigenic reactivity. Five peptides (MKIRSVRPLVVLLVC, RSVRPLVVLLVCVAA, RPLVVLLVCVAAVLA, VVLLVCVAAVLALSA and LVCVAAVLALSASAE) corresponding to the non-repetitive N-terminal part of rec*Ld*VFA2 were strongly reactive (peptides 1--5) with all four anti- recVFA2 dog serum tested ([Fig 1](#pntd.0005562.g001){ref-type="fig"}). Sera from non-immunized dogs were used as negative control showing no reactivity with membrane spots. When mAb anti-rec*Ld*VFA2 was used, spots corresponding to the non-repetitive N-ter region didn't react. However, all peptides of the repetitive C-ter region showed some degree of reactivity ([Fig 2](#pntd.0005562.g002){ref-type="fig"}). Peptide number 48 (PLSVGPQAVGPLSVG) was the more strongly reactive ([Table 2](#pntd.0005562.t002){ref-type="table"}). Synthetic peptides of the repetitive region containing two replicates of the amino acid sequence PLSVG (peptides number 13, 23, 38, 48 and 52) showed high reactivity with the mAb and can be considered immunodominant epitopes of the repetitive region. However, some peptides containing only a single PLSVG motif also reacted quite strongly (peptides 27, 52, 75) with mAb.

![Binding pattern of a dog policlonal antibodies with the overlapping peptides.\
(A) Reactivity of 15-mer overlapping peptides derived from the amino acid sequence of A2 protein with dog serum (pAb). Peptides were prepared by the Spot method on cellulose membranes (Section 2) and dogs anti-A2 antibody binding (serum diluted 1:100) to cellulose-bound peptides was detected by an alkaline phosphatase-coupled anti-dog antibody (diluted 1:2000). (B) Percentage of reactivity of each peptide recognized by dog antisera A2 protein. The reactive peptides were: MKIRSVRPLVVLLVC, RSVRPLVVLLVCVAA, RPLVVLLVCVAAVLA, VVLLVCVAAVLALSA and LVCVAAVLALSASAE.](pntd.0005562.g001){#pntd.0005562.g001}

![Binding pattern of a murine monoclonal antibodies with the overlapping peptides.\
(A) Reactivity of 15-mer overlapping peptides derived from the amino acid sequence of A2 protein with a murine monoclonal antibody (mAb). The mAb binding (concentration in 2.0 μg/mL) to cellulose-bound peptides was detected by an alkaline phosphatase-coupled anti-dog antibody (diluted 1:2000). (B) Percentage of reactivity of each peptide recognized by anti-A2 protein murine mAb. The more reactive peptide was PLSVGPQAVGPLSVG.](pntd.0005562.g002){#pntd.0005562.g002}

10.1371/journal.pntd.0005562.t002

###### Seventy-five overlapping decapentapeptides synthesized corresponding to the complete amino acid sequence of A2 *Leishmania sp* protein.

![](pntd.0005562.t002){#pntd.0005562.t002g}

  ---------------------------------------------------------------------------------------------------------------------------
  \                \                   \                  \           \          \                                
  Peptide number   Peptide\            Color intensity\   Peptide\    Peptide\   Color intensity\                 
                   Sequence            (mAb) (pAbs)       number      sequence   (mAb) (pAbs)                     
  ---------------- ------------------- ------------------ ----------- ---------- ------------------- ------------ -----------
  \                \                   \                  \           \          \                   \            \
  **1**            `MKIRSVRPLVVLLVC`   **11.10**          **96.13**   **39**     `VGPQSVGPLSVGPQA`   **49.95**    **20.22**

  **2**            `RSVRPLVVLLVCVAA`   **13.43**          **84.25**   **40**     `QSVGPLSVGPQAVGP`   **39.85**    **22.07**

  **3**            `RPLVVLLVCVAAVLA`   **5.34**           **99.79**   **41**     `GPLSVGPQAVGPLSV`   **63.11**    **20.82**

  **4**            `VVLLVCVAAVLALSA`   **6.95**           **87.53**   **42**     `SVGPQAVGPLSVGPQ`   **52.71**    **16.86**

  **5**            `LVCVAAVLALSASAE`   **10.62**          **80.68**   **43**     `PQAVGPLSVGPQSVG`   **29.71**    **19.54**

  **6**            `VAAVLALSASAEPHK`   **12.36**          **36.52**   **44**     `VGPLSVGPQSVGPLS`   **49.13**    **25.01**

  **7**            `VLALSASAEPHKAAV`   **7.94**           **26.89**   **45**     `LSVGPQSVGPLSVGP`   **63.51**    **26.16**

  **8**            `LSASAEPHKAAVDVG`   **10.69**          **19.40**   **46**     `GPQSVGPLSVGPQAV`   **26.72**    **17.06**

  **9**            `SAEPHKAAVDVGPLS`   **22.77**          **31.91**   **47**     `SVGPLSVGPQAVGPL`   **60.71**    **29.32**

  **10**           `PHKAAVDVGPLSVGP`   **70.96**          **32.71**   **48**     `PLSVGPQAVGPLSVG`   **100.00**   **35.31**

  **11**           `AAVDVGPLSVGPQSV`   **26.67**          **20.70**   **49**     `VGPQAVGPLSVGPQS`   **71.15**    **36.22**

  **12**           `DVGPLSVGPQSVGPL`   **49.65**          **29.34**   **50**     `QAVGPLSVGPQSVGP`   **55.11**    **26.75**

  **13**           `PLSVGPQSVGPLSVG`   **85.37**          **29.66**   **51**     `GPLSVGPQSVGPLSV`   **65.83**    **22.91**

  **14**           `VGPQSVGPLSVGPQA`   **46.38**          **24.66**   **52**     `SVGPQSVGPLSVGPQ`   **98.62**    **30.74**

  **15**           `QSVGPLSVGPQAVGP`   **43.93**          **22.79**   **53**     `PQSVGPLSVGPQSVG`   **69.84**    **29.47**

  **16**           `GPLSVGPQAVGPLSV`   **44.48**          **25.30**   **54**     `VGPLSVGPQSVGPLS`   **79.79**    **24.82**

  **17**           `SVGPQAVGPLSVGPQ`   **61.76**          **24.81**   **55**     `LSVGPQSVGPLSVGS`   **42.65**    **16.10**

  **18**           `PQAVGPLSVGPQSVG`   **54.83**          **24.64**   **56**     `GPQSVGPLSVGSQSV`   **32.33**    **21.36**

  **19**           `VGPLSVGPQSVGPLS`   **56.06**          **25.01**   **57**     `SVGPLSVGSQSVGPL`   **37.82**    **20.93**

  **20**           `LSVGPQSVGPLSVGP`   **67.72**          **25.85**   **58**     `PLSVGSQSVGPLSVG`   **56.15**    **26.50**

  **21**           `GPQSVGPLSVGPQAV`   **28.75**          **21.04**   **59**     `VGSQSVGPLSVGPQS`   **38.19**    **24.80**

  **22**           `SVGPLSVGPQAVGPL`   **57.10**          **32.53**   **60**     `QSVGPLSVGPQSVGP`   **35.07**    **18.11**

  **23**           `PLSVGPQAVGPLSVG`   **98.23**          **34.70**   **61**     `GPLSVGPQSVGPLSV`   **47.65**    **19.07**

  **24**           `VGPQAVGPLSVGPQS`   **51.55**          **25.26**   **62**     `SVGPQSVGPLSVGPQ`   **58.78**    **21.28**

  **25**           `QAVGPLSVGPQSVGP`   **55.71**          **27.91**   **63**     `PQSVGPLSVGPQSVG`   **38.64**    **21.87**

  **26**           `GPLSVGPQSVGPLSV`   **65.37**          **18.03**   **64**     `VGPLSVGPQSVGPLS`   **44.45**    **23.09**

  **27**           `SVGPQSVGPLSVGPL`   **89.87**          **27.24**   **65**     `LSVGPQSVGPLSVGP`   **54.45**    **23.85**

  **28**           `PQSVGPLSVGPLSVG`   **79.92**          **24.14**   **66**     `GPQSVGPLSVGPQSV`   **30.19**    **18.21**

  **29**           `VGPLSVGPLSVGPQS`   **74.04**          **26.81**   **67**     `SVGPLSVGPQSVGPL`   **50.46**    **25.96**

  **30**           `LSVGPLSVGPQSVGP`   **42.24**          **25.79**   **68**     `PLSVGPQSVGPLSVG`   **74.70**    **31.42**

  **31**           `GPLSVGPQSVGPLSV`   **67.67**          **22.16**   **69**     `VGPQSVGPLSVGPQS`   **44.99**    **20.80**

  **32**           `SVGPQSVGPLSVGSQ`   **42.65**          **18.23**   **70**     `QSVGPLSVGPQSVGP`   **31.64**    **24.81**

  **33**           `PQSVGPLSVGSQSVG`   **26.41**          **20.62**   **71**     `GPLSVGPQSVGPLSV`   **49.29**    **25.41**

  **34**           `VGPLSVGSQSVGPLS`   **35.39**          **19.50**   **72**     `SVGPQSVGPLSVGPQ`   **51.17**    **18.40**

  **35**           `LSVGSQSVGPLSVGP`   **58.37**          **25.74**   **73**     `PQSVGPLSVGPQSVD`   **58.78**    **32.72**

  **36**           `GSQSVGPLSVGPQSV`   **36.10**          **21.20**   **74**     `VGPLSVGPQSVDVSP`   **53.32**    **27.61**

  **37**           `SVGPLSVGPQSVGPL`   **34.83**          **24.31**   **75**     `PLSVGPQSVDVSPVS`   **97.48**    **32.82**

  **38**           `PLSVGPQSVGPLSVG`   **83.90**          **27.51**                                               
  ---------------------------------------------------------------------------------------------------------------------------

Diagnosis of canine leishmaniasis using synthetic bi-epitope in an ELISA format {#sec021}
-------------------------------------------------------------------------------

A 34-mer recVFA2-derived synthetic peptide containing the sequence MKIRSVRPLVVLLVC linked by a Gly-Gly to the sequence PLSVGPQAVGPLSVG was chemically synthesized. Two amino acids were added, a Lys to the N-ter and a Cys to the C-ter regions, respectively. This synthetic peptide (bi-epitope) was used as antigen to coat ELISA plates, for an immune diagnosis of CVL. ELISA parameters (eg. antigen concentration, incubation times, serum dilution) were previously defined.

A ready to use commercial EIE-LVC kit was included for performance comparison ([Fig 3](#pntd.0005562.g003){ref-type="fig"}). In the conditions previously defined, the bi-epitope showed better diagnostic performance (AUC = 0.9987, 95% CI 0.9967 to 1.001; ACC = 0.9851) when compared to EIE-LVC kit (AUC = 0.9601, 95% CI 0.9351 to 0.9850; ACC = 0.9001) ([Table 3](#pntd.0005562.t003){ref-type="table"}). rec*Ld*VFA2 showed sensitivity (98.02%; 95% CI 93.03 to 99.76%) and specificity (99.01%; 95% CI 94,61 to 99.97%) values for detection CVL higher than those obtained with EIE-LVC kit (Se and Sp = 90.01%; 95% CI 82.54 to 95.15%). Bi-epitope ELISA was also able to discriminate *Leishmania*-infected animals from animals infected with *T*. *cruzi*, however EIE-LVC kit show cross-reactivity with *T*. *cruzi*-infected sera ([Fig 3A and 3B](#pntd.0005562.g003){ref-type="fig"}).

![Comparison of ELISA reactivity and ROC curves obtained from canine sera against recLdVFA2 and antigen of EIE-LVC kit.\
**(**A) ELISA reactivity obtained from dogs sera against EIE-LVC kit. (B) ELISA reactivity obtained from dogs sera against recLdVFA2 bi-epitope. The ELISA was performed with groups of 101 uninfected dogs (NI), 101 infected with *Leishmania* (I) and 10 infected with *Trypanosoma cruzi* (TC). (C) ROC curve obtained from EIE-LVC kit. (D) ROC curve obtained from recLdVFA2 bi-epitope. The ROC curves were used to determine cut-off, sensitivity, specificity and AUC. Data variation expressed as standard error. \*Cut-off obtained by ROC curve and \#Cut-off obtained according to kit manufacturer.](pntd.0005562.g003){#pntd.0005562.g003}

10.1371/journal.pntd.0005562.t003

###### Diagnostic performance for rec*Ld*VFA2 and EIE-LVC kit.

![](pntd.0005562.t003){#pntd.0005562.t003g}

  -------------------------------------------------------------------------------------------------------------------
                   Test                                          
  ---------------- --------------------------------------------- ----------------------------------------------------
  Cut-off          0.4710[\*](#t003fn001){ref-type="table-fn"}   0.0665[\*](#t003fn001){ref-type="table-fn"}

  AUC              0.9987                                        0.9601

  ACC              0.9851                                        0.9010

  Se (95% CI)      98.02% (93.03--99.76%)                        0.9010% (82.54--95.15%)

  Sp (95% CI)      99.01% (94.61--99.97%)                        0.9010% (82.54--95.15%)

  PPV              0.99                                          0.90

  NPV              0.98                                          0.90

  Kappa (95% CI)   0.97(0.937--1.00)\                            0.802 (0.720--0.884)\
                   (very good)                                   (very good)[^\#^](#t003fn002){ref-type="table-fn"}
  -------------------------------------------------------------------------------------------------------------------

\*Cut-off obtained by ROC curve

\#With cut-off obtained according to kit manufacturer the agreement is "good"

Agreement was calculated using parasitological assays as gold standard test.

Abbreviations: AUC: area under curve; ACC: accuracy; Se: sensitivity; Sp: specificity; PPV: positive predictive value; NPV: negative predictive value; CI: confidence interval.

Discussion {#sec022}
==========

*Ld*VFA2 protein was identified as an important candidate for vaccine development against visceral leishmaniasis \[[@pntd.0005562.ref011], [@pntd.0005562.ref013], [@pntd.0005562.ref025]\].

B-cell epitope in *Ld*VFA2 was previously located within the repetitive units using sera from rec*Ld*VFA2-vaccinated mice and with the *Ld*VFA2-specific monoclonal antibody \[[@pntd.0005562.ref010]\]. A recent study has demonstrated that humoral response to rec*Ld*VFA2 in dogs is associated, presumably, with protective immunity against *Leishmania spp*. parasites \[[@pntd.0005562.ref026]\], however, B-cell epitope analysis with antibodies elicited in dogs were not conducted. Thus, researches for diagnosis or vaccines applied to dogs could be eventually improved by the identification of B-cell epitope mapping of *Ld*VFA2, using homologous antibodies. In this way, the present study, provided mapping of continuous B-cell epitopes, using sera from rec*Ld*VFA2 immunized dogs and a mouse monoclonal antibody (anti-rec*Ld*VFA2 mAb), by performing a systematic 15 mer peptide-scan along the complete rec*Ld*VFA2 sequence.

Anti-rec*Ld*VFA2 dog sera recognize peptides derived from the non-repetitive N-term region of rec*Ld*VFA2. Immunoreactivity of peptides bound to membranes reveals five sequences containing epitopes close to this region (peptides 1--15, 4--18, 7--21, 10--24 and 13--27). B-cell epitopes within the repetitive C-term region were not identified. On the other hand using an anti-*Ld*VFA2 mAb, B-cell epitopes in rec*Ld*VFA2 were located solely within the repetitive units, which is consistent with a previous report \[[@pntd.0005562.ref027]\]. The two most reactive peptides have two repetitions of the sequence PLSVG (spots 23 and 48: region 67--81 and 122--135). This sequence PLSVGPQAVGPLSVG is repeated four times in the complete sequence of the *Ld*VFA2 protein. Spots 13 and 38 are also very reactive and have only one substitution in its sequence (alanine for serine), when compared to the spots 23 e 48. Thus, residues PLSVG-(X)~5~ --PLSVG are key contributors to the antigenic recognition of the peptide by specific mAb. However, spots 27 and 75 have only one sequence PLSVG and are also very reactive. We do not have a clear explanation for this observation.

A rec*Ld*VFA2 derived chimeric peptide based on mapped continuous B-cell epitopes MKIRSVRPLVVLLVC and PLSVGPQAVGPLSVG was synthesized and used in ELISA experiments for serum diagnosis of CVL. In fact, we prepared 34-mer rec*Ld*VFA2-derived peptides containing a sequence of 15 residues from one part of rec*Ld*VFA2 linked by a Gly-Gly dipeptide to a pentadeca sequence from another part of the protein, in order to bring together regions that are apart from each other in the linear sequence of the recombinant peptide. Glycine spacers' separating the peptides increases their recognition by antibodies by providing a better exposition of chains for interaction \[[@pntd.0005562.ref028]\]. N-ter and C-ter extremities were capped respectively by a Lysine and a Cysteine residue to allow further specific coupling to protein carriers (not used in this work). The 34-mer bi-epitope peptide was used as coating antigen in an ELISA format.

Accurate diagnosis of canine leishmaniasis is essential towards a more efficient control of this zoonosis, but is no yet achieved due to the high incidence of serological cross-reactions, mainly with other tripanosomatids antigens in canine serum samples \[[@pntd.0005562.ref029]\]. The use of synthetic peptides \[[@pntd.0005562.ref030], [@pntd.0005562.ref031]\] as antigens in diagnosis of canine leishmaniasis may limit cross reactivity. It would also circumvent reliance on parasite extracts, which are not easy to reproducibly produce, and thus may help assay standardization. In the present work, encouraging results were obtained using the synthetic bi-epitope as coating antigen. Bi-epitope ELISA diagnostic test showed better sensitivity and specificity than the EIE-LVC kit, which is considered the gold standard for CVL diagnosis and high degree of agreement with parasitological techniques for the leishmaniasis diagnosis. These results using peptides selected by a peptide scanning method showed a better performance than others studies with synthetic peptides for CVL immunodiagnosis tests \[[@pntd.0005562.ref032], [@pntd.0005562.ref033], [@pntd.0005562.ref030], [@pntd.0005562.ref034]\].

In conclusion, data presented in the current study suggest that it is feasible to map B-cell epitopes from an overlapping peptide library covering the full length of rec*Ld*VFA2 and to further use the selected peptides in combination to diagnose canine visceral leishmaniasis. Further studies using sera of dogs from endemic areas (with high and low CVL prevalence) are obviously required to determine the use of these antigens for field control of CVL. Bi-epitope is derived from A2 protein and Leish-Tec vaccine is produced from this protein, so if it used in a diagnostic test of CVL, it may not be able to discriminate infected animals from those vaccinated. This antigen can be used in regions where this vaccine is not used and can also be combined with other antigenic epitopes that can minimize this fact. Finally, our work suggests that synthetic peptide-based ELISA strategy may be useful for the development of a sensitive and highly specific serodiagnosis for CVL or other parasitic diseases.
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